Markets across the world are trying to grapple with coronavirus hitting China's production capabilities. Some experts believe that the impact will be short-term as things should be under control sooner than later.
CNBC-TV18 spoke to Geoffrey Dennis, an emerging markets commentator, and James Glassman, senior economist at JPMorgan Chase to get an in-depth impact analysis.
James Glassman believes that there will be negligible long-term impact. “This is going to be very transitory because China is already getting back to work. It is going to take a few more weeks before they get back to something more normal but this is a first-quarter phenomenon and for economists, when we think about the year as a whole, I see no change in views about the global economy compared with a couple of months ago. So it is not anything that makes sense to an economist. It is just purely based on fear and we know that it is going to be transitory.”
Dennis agreed with Glassman and also said that the situation could become a buying opportunity eventually.
"I am not sure if it is a buying opportunity yet though it will be a buying opportunity ultimately. The problem is we don’t know how much this thing is going to spread and as James Glassman said, the reason why the markets are very weak today is because of the clear evidence that it is spreading to other countries like Italy, Iran, South Korea and so there are increasing fears about the global nature of this virus. I think he is certainly right that ultimately the impact on the global economy will peter out, it will be reversed in time but I think the markets are well ahead of themselves. Anyways there was a lot of complacency about it," he said.
Frequently Asked Questions
A vaccine works by mimicking a natural infection. A vaccine not only induces immune response to protect people from any future COVID-19 infection, but also helps quickly build herd immunity to put an end to the pandemic. Herd immunity occurs when a sufficient percentage of a population becomes immune to a disease, making the spread of disease from person to person unlikely. The good news is that SARS-CoV-2 virus has been fairly stable, which increases the viability of a vaccine.
There are broadly four types of vaccine — one, a vaccine based on the whole virus (this could be either inactivated, or an attenuated [weakened] virus vaccine); two, a non-replicating viral vector vaccine that uses a benign virus as vector that carries the antigen of SARS-CoV; three, nucleic-acid vaccines that have genetic material like DNA and RNA of antigens like spike protein given to a person, helping human cells decode genetic material and produce the vaccine; and four, protein subunit vaccine wherein the recombinant proteins of SARS-COV-2 along with an adjuvant (booster) is given as a vaccine.
Vaccine development is a long, complex process. Unlike drugs that are given to people with a diseased, vaccines are given to healthy people and also vulnerable sections such as children, pregnant women and the elderly. So rigorous tests are compulsory. History says that the fastest time it took to develop a vaccine is five years, but it usually takes double or sometimes triple that time.
The near-term impact seems tough though.
"It is going to be very disruptive in the near-term and the reason it is so disruptive economically is that China had to quarantine large communities and they were not able to get back to work after the Chinese New Year. It is slowly happening. We have actually lost more people from flu than we have from this virus. I think that the fears about this are exaggerated. I think it will be very disruptive for a few months and then when we get into the spring quarter, you are going to see a very strong rebound," Glassman stated.Source: CNBC-TV18